Related Experiment Videos
Recent clinical trials in acute coronary syndromes without persistent ST elevation
1Duke University Medical Center, Durham, North Carolina 27710, USA. tolle004@onyx.dcri.duke.edu
Insights
Acute coronary syndromes (ACS) are serious heart conditions. Current treatments include aspirin, heparin, enoxaparin, and glycoprotein IIb/IIIa inhibitors, with ongoing research into optimal early intervention strategies.
Area of Science:
- Cardiology
- Internal Medicine
- Emergency Medicine
Background:
- Acute coronary occlusion, a critical aspect of coronary artery disease, results in substantial morbidity and mortality.
- Traditional classifications like Q-wave myocardial infarction are evolving towards acute coronary syndromes (ACS) with and without ST-segment elevation for better clinical guidance.
Purpose of the Study:
- To review the current understanding and management of acute coronary syndromes.
- To highlight evolving treatment strategies and the need for further clinical trials.
Main Methods:
- Review of current therapeutic agents including aspirin, heparin, enoxaparin, and glycoprotein IIb/IIIa inhibitors.
- Discussion of the ongoing debate regarding early intervention versus conservative management.
Main Results:
- Standard therapies have been augmented by newer agents like enoxaparin and glycoprotein IIb/IIIa inhibitors.
- The optimal timing and approach to intervention remain subjects of active clinical investigation.
Conclusions:
- Acute coronary syndromes require prompt and evolving treatment strategies.
- Continued clinical trials are essential to refine optimal management for this high-risk patient population.
Abstract:
Acute coronary occlusion is a serious manifestation of coronary artery disease leading to significant short- and long-term morbidity and mortality. Traditionally classified as Q-wave myocardial infarction, non-Q-wave myocardial infarction, and unstable angina, these events are more appropriately termed acute coronary syndromes with and without ST-segment elevation, reflecting the diagnostic criteria used by clinicians to guide initial treatment strategies. Standard therapy with aspirin and heparin has been expanded with the low molecular weight heparin enoxaparin and the intravenous glycoprotein IIb/IIIa inhibitors eptifibatide and tirofiban. Debate continues as to whether a strategy of early intervention or initial conservative management is most appropriate. Continued clinical trials will help define optimal treatment strategies in this high-risk group of patients.